Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 15 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Oruka Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 25 | 23 | −2 |
| Shares | 7.48M | 7.20M | −278.4K (−3.7%) |
| Value | $12.7M | $12.7M | −$35.6K (−0.3%) |
New holders (2)
Institutions that held Oruka Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 12,714 | $22.0K | 0.00% |
| FMR LLC | 201 | $358 | 0.00% |
Sold out (4)
Institutions that held Oruka Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Newtyn Management, LLC | 269,320 | $457.8K |
| Two Sigma Securities, LLC | 12,119 | $20.6K |
| UBS Group AG | 1,131 | $1.92K |
| Advisor Group Holdings, Inc. | 55 | $93 |